PDS Biotechnology (PDSB) Accumulated Depreciation (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Accumulated Depreciation came in at $175727.0 in Q4 2025, up 14.19% YoY from $153891.0 in Q4 2024, and up 14.19% on a QoQ basis from $153891.0 in Q4 2024.
PDS Biotechnology (PDSB) Accumulated Depreciation (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Accumulated Depreciation data on file, last reported at $175727.0 in Q4 2025.
- Quarterly Accumulated Depreciation rose 14.19% year-over-year to $175727.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $175727.0 (up 14.19% YoY) and the FY2025 annual result came in at $175727.0, up 14.19% from the prior year.
- Accumulated Depreciation grew to $175727.0 in Q4 2025, from $153891.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $175727.0 in Q4 2025 to a low of $115334.0 in Q4 2021.
- A 5-year average of $138630.2 and a median of $132779.0 in 2023 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation grew 0.07% — and 2024, when it rose 15.9%.
- Tracing PDSB's Accumulated Depreciation over 5 years: stood at $115334.0 in 2021, then grew by 0.07% to $115420.0 in 2022, then advanced by 15.04% to $132779.0 in 2023, then rose by 15.9% to $153891.0 in 2024, then rose by 14.19% to $175727.0 in 2025.
- The last three Accumulated Depreciation figures came in at $175727.0 (Q4 2025), $153891.0 (Q4 2024), and $132779.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 175,727.00 |
| Dec 31, 2024 | 153,891.00 |
| Dec 31, 2023 | 132,779.00 |
| Dec 31, 2022 | 115,420.00 |
| Dec 31, 2021 | 115,334.00 |
| Dec 31, 2020 | 109,977.00 |
| Dec 31, 2019 | 94,369.00 |
| Dec 31, 2018 | 72,291.00 |
| Dec 31, 2017 | 305,281.00 |
| Dec 31, 2016 | 122,363.00 |
| Dec 31, 2015 | 91,392.00 |
| Dec 31, 2014 | 38,276.00 |